Rimjhim Pathak¹, Prem Saran Tirumalai²* and Seema Kashyap¹

¹Dayalbagh Educational Institute, Department of Home Science, Dayalbagh, Uttar Pradesh, India
²Dayalbagh Educational Institute, Department of Agricultural sciences (Botany), Food and Dairy Testing Lab Dayalbagh, Uttar Pradesh, India

*Corresponding Author: Prem Saran Tirumalai, Dayalbagh Educational Institute, Department of Agricultural sciences (Botany), Food and Dairy Testing Lab Dayalbagh, Uttar Pradesh, India.

Received: September 11, 2023; Published: November 07, 2023

Abstract

The journey from the discovery of normal flora to gut microbes and the resulting field of probiotics and psychobiotics has been a long and fascinating one. From the time normal flora and gut microbes came to be known researchers began to realize that these microorganisms played an important role in maintaining human health playing a crucial role in digestion, immunity, and even mental health. This led to the development of probiotics, which when ingested in adequate amounts, confer health benefits to the host. Probiotics have been shown to help treat a variety of health conditions, including gastrointestinal disorders, allergies, and even depression and anxiety. More recently, the field of psychobiotics has emerged, which refers to the use of probiotics and other dietary interventions to improve mental health. This field is still in its early stages, but initial studies suggest that certain probiotics may be effective in treating depression, anxiety, and other mental health disorders. This article reviews the emergence of Psychobiotics and discusses related topics and findings in context.

Keywords: Psychobiotics; Probiotics; Gut Microbes; Gut-Brain Axis

References

1. Bäckhed F., et al. “Dynamics and stabilization of the human gut microbiome during the first year of life". Cell Host and Microbe5 (2015): 690-703.
2. Tanaka M and Nakayama J. “Development of the gut microbiota in infancy and its impact on health in later life”. Allergology International4 (2017): 515-522.
3. Johnson D., et al. “Exploring the role and potential of probiotics in the field of mental health: Major depressive disorder”. Nutrients5 (2017): 1728.
4. Hold GL., et al. “Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiology Ecology1 (2002): 33-39.
5. Ringel‐Kulka T., et al. “Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain‐a randomised clinical study”. Alimentary Pharmacology and Therapeutics2 (2014): 200-207.
6. Salazar N., et al. “Nutrition and the gut microbiome in the elderly”. Gut Microbes2 (2017): 82-97.
7. Yatsunenko T., et al. “Human gut microbiome viewed across age and geography”. Nature 7402 (2012): 222-227.
8. Conlon M A and Bird A R. “The impact of diet and lifestyle on gut microbiota and human health”. Nutrients1 (2015): 17-44.
9. Lyte M., et al. “Stress at the intestinal surface: catecholamines and mucosa–bacteria interactions”. Cell and Tissue Research 343 (2011): 23-32.
10. Strati F., et al. “Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models”. Microbiome 9 (2021): 1-15.
11. Wardwell L H., et al. “Current concepts of the intestinal microbiota and the pathogenesis of infection”. Current Infectious Disease Reports 13 (2011): 28-34.
12. Qamar A., et al. “The role of intestinal microbiota in chicken health, intestinal physiology and immunity”. JAPS: Journal of Animal and Plant Sciences2 (2021).
13. Nie Y., et al. “Dietary nutrition and gut microflora: A promising target for treating diseases”. Trends in Food Science and Technology 75 (2018): 72-80.
14. Gao R., et al. “Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity”. Obesity2 (2018): 351-361.
15. Li J., et al. “Clostridiales are predominant microbes that mediate psychiatric disorders”. Journal of Psychiatric Research 130 (2020): 48-56.
16. Zuo T and Ng S C. “The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease”. Frontiers in Microbiology 9 (2018): 2247.
17. Cantarel BL., et al. “Gut microbiota in multiple sclerosis: possible influence of immunomodulators”. Journal of Investigative Medicine5 (2015): 729-734.
18. Vivarelli S., et al. “Gut microbiota and cancer: from pathogenesis to therapy”. Cancers1 (2019): 38.
19. Lynch SV. “Gut microbiota and allergic disease. New insights”. Annals of the American Thoracic Society 13 (2016): S51-S54.
20. Benakis C., et al. “Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells”. Nature Medicine5 (2016): 516-523.
21. Dinan T G and Cryan J F. “Brain-gut-microbiota axis and mental health”. Psychosomatic Medicine8 (2017): 920-926.
22. Liu Y W., et al. “Psychotropic effects of Lactobacillus plantarum PS128 in early life-stressed and naïve adult mice”. Brain Research 1631 (2016): 1-12.
23. Sampson TR., et al. “Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease”. Cell 6 (2016): 1469-1480.
24. Minter MR., et al. “Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease”. Scientific Reports1 (2016): 30028.
25. Marazziti D., et al. “The Microbiota/Miscrobiome and the Gut–Brain Axis: How Much Do They Matter in Psychiatry?”. Life8 (2021): 760.
26. Westfall S., et al. “Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis”. Cellular and molecular life sciences 74 (2021): 3769-3787.
27. Rea K., et al. “Gut microbiota: a perspective for psychiatrists”. Neuropsychobiology1 (2020): 50-62.
28. Yano JM., et al. “Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis”. Cell 2 (2015): 264-276.
29. Lyte M. “Microbial endocrinology: host-microbiota neuroendocrine interactions influencing brain and behavior”. Gut Microbes3 (2014): 381-389.
30. Sarkodie E K., et al. “Influences of stress hormones on microbial infections”. Microbial Pathogenesis 131 (2019): 270-276.
31. Graversen K B., et al. “Short-term amoxicillin-induced perturbation of the gut microbiota promotes acute intestinal immune regulation in brown Norway rats”. Frontiers in Microbiology 11 (2020): 496.
32. Mittal R., et al. “Neurotransmitters: The critical modulators regulating gut–brain axis”. Journal of Cellular Physiology 9 (2017): 2359-2372.
33. Balakrishnan M and Floch MH. “Prebiotics, probiotics and digestive health”. Current Opinion in Clinical Nutrition and Metabolic Care6 (2012): 580-585.
34. Suez J., et al. “Artificial sweeteners induce glucose intolerance by altering the gut microbiota”. Nature 7521 (2015): 181–186.
35. Cunningham-Rundles S., et al. “Probiotics and immune response”. The American Journal of Gastroenterology1 (2000): S22-S25.
36. Ebel B., et al. “Impact of probiotics on risk factors for cardiovascular diseases. A review”. Critical reviews in Food Science and Nutrition2 (2014): 175-189.
37. Ruddick J P., et al. “Tryptophan metabolism in the central nervous system: medical implications”. Expert Reviews in Molecular Medicine2 (2006): 0 1-27.
38. Morita C., et al. “Gut dysbiosis in patients with anorexia nervosa”. PloS One12 (2015): e0145274.
39. Zhang L., et al. “Altered gut microbiota in a mouse model of Alzheimer’s disease”. Journal of Alzheimer's Disease 4 (2017): 1241-1257.
40. Unger M M., et al. “Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls”. Parkinsonism and Related Disorders 32 (2016): 66-72.
41. Maltz R M., et al. “Prolonged restraint stressor exposure in outbred CD-1 mice impacts microbiota, colonic inflammation, and short chain fatty acids”. PloS one5 (2018): e0196961.
42. Liu S., et al. “Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder”. Scientific Reports1 (2019): 287.
43. Erny D., et al. “Host microbiota constantly control maturation and function of microglia in the CNS”. Nature Neuroscience 7 (2015): 965-977.
44. Baxter N T., et al. “Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers”. MBio1 (2019): e02566-18.
45. Macfarlane S and Macfarlane GT. “Regulation of short-chain fatty acid production”. Proceedings of the Nutrition Society1 (2003): 67-72.
46. McOrist A L., et al. “Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch”. The Journal of Nutrition 5 (2011): 883-889.
47. Shukla S and Tekwani B L. “Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation”. Frontiers in Pharmacology 11 (2020): 537.
48. Mossad O and Erny D. “The microbiota–microglia axis in central nervous system disorders”. Brain Pathology6 (2020): 1159-1177.
49. Lyte M. “Microbial endocrinology: host-microbiota neuroendocrine interactions influencing brain and behavior”. Gut Microbes3 (2014): 381-389.
50. Iyer LM., et al. “Evolution of cell–cell signaling in animals: did late horizontal gene transfer from bacteria have a role?”. TRENDS in Genetics7 (2004): 292-299.
51. Smith D K., et al. “Escherichia coli has two homologous glutamate decarboxylase genes that map to distinct loci”. Journal of Bacteriology18 (1992): 5820-5826.
52. Strandwitz P., et al. “GABA-modulating bacteria of the human gut microbiota”. Nature Microbiology3 (2019): 396-403.
53. Matsumoto M., et al. “Impact of intestinal microbiota on intestinal luminal metabolome”. Scientific Reports1 (2012): 233.
54. Pokusaeva K., et al. “GABA‐producing Bifidobacterium dentium modulates visceral sensitivity in the intestine”. Neurogastroenterology and Motility1 (2017): e12904.
55. Luck B., et al. “Neurotransmitter profiles are altered in the gut and brain of mice mono-associated with Bifidobacterium dentium”. Biomolecules 8 (2021): 1091.
56. Makizaki Y., et al. “Improvement of loperamide-induced slow transit constipation by Bifidobacterium bifidum G9-1 is mediated by the correction of butyrate production and neurotransmitter profile due to improvement in dysbiosis”. PLoS One3 (2021): e0248584.
57. Halverson T and Alagiakrishnan K. “Gut microbes in neurocognitive and mental health disorders”. Annals of Medicine 8 (2020): 423-443.
58. Foster J A., et al. “Stress and the gut-brain axis: regulation by the microbiome”. Neurobiology of Stress 7 (2021): 124-136.
59. Davis I and Liu A. “What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?”. Expert Review of Neurotherapeutics7 (2015): 719-721.
60. Marin IA., et al. “Microbiota alteration is associated with the development of stress-induced despair behavior”. Scientific Reports1 (2017): 43859.
61. Dodd D., et al. “A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites”. Nature 7682 (2017): 648-652.
62. Vasey C., et al. “Circadian rhythm dysregulation and restoration: the role of melatonin”. Nutrients10 (2021): 3480.
63. Bravo R., et al. “Tryptophan-enriched cereal intake improves nocturnal sleep, melatonin, serotonin, and total antioxidant capacity levels and mood in elderly humans”. Age 35 (2013): 1277-1285.
64. Zhou B., et al. “Lactobacillus rhamnosus GG colonization in early life regulates gut-brain axis and relieves anxiety-like behavior in adulthood”. Pharmacological Research 177 (2022): 106090.
65. Messaoudi M., et al. “Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects”. British Journal of Nutrition 5 (2011): 755-764.
66. Sudo N., et al. “Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice”. The Journal of Physiology1 (2004): 263-275.
67. Bercik P., et al. “The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication”. Neurogastroenterology and Motility12 (2011): 1132-1139.
68. Tian P., et al. “Bifidobacterium with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis”. The Journal of Nutritional Biochemistry 66 (2019): 43-51.
69. Savignac H M., et al. “Bifidobacteria exert strain‐specific effects on stress‐related behavior and physiology in BALB/c mice”. Neurogastroenterology and Motility11 (2014): 1615-1627.
70. Kobayashi Y., et al. “Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease”. Scientific Reports1 (2017): 1-10.
71. Yunes R A., et al. “A multi-strain potential probiotic formulation of GABA-producing Lactobacillus plantarum 90sk and Bifidobacterium adolescentis 150 with antidepressant effects”. Probiotics and Antimicrobial proteins 12 (2020): 973-979.
72. Davis D J., et al. “Lactobacillus plantarum attenuates anxiety-related behavior and protects against stress-induced dysbiosis in adult zebrafish”. Scientific Reports1 (2016): 1-11.
73. Liang S., et al. “Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress”. Neuroscience 310 (2015): 561-577.
74. Wang T., et al. “Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats”. Beneficial Microbes5 (2015): 707-717.
75. Takada M., et al. “Probiotic Lactobacillus casei strain Shirota relieves stress‐associated symptoms by modulating the gut–brain interaction in human and animal models”. Neurogastroenterology and Motility7 (2016): 1027-1036.
76. Jang H M., et al. “The preventive and curative effects of Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 on immobilization stress-induced anxiety/depression and colitis in mice”. Nutrients4 (2019): 819.
77. Maehata H., et al. “Heat-killed Lactobacillus helveticus strain MCC1848 confers resilience to anxiety or depression-like symptoms caused by subchronic social defeat stress in mice”. Bioscience, Biotechnology, and Biochemistry 7 (2019): 1239-1247.
78. Jeon S., et al. “Positive effect of Lactobacillus acidophilus EG004 on cognitive ability of healthy mice by fecal microbiome analysis using full-length 16S-23S rRNA metagenome sequencing”. Microbiology Spectrum 1 (2022): e01815-21.
79. Vaghef-Mehrabany E., et al. “Calorie restriction in combination with prebiotic supplementation in obese women with depression: effects on metabolic and clinical response”. Nutritional Neuroscience5 (2021): 339-353.
80. Wallace C J and Milev R V. “The efficacy, safety, and tolerability of probiotics on depression: clinical results from an open-label pilot study”. Frontiers in Psychiatry 12 (2021): 618279.
81. Salleh RM., et al. “Effects of probiotics on anxiety, stress, mood and fitness of badminton players”. Nutrients, 13.6 (2021): 1783.
82. Pinto-Sanchez M I., et al. “Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome”. Gastroenterology (2017).
83. Dong W., et al. “Bifidobacterium animalis subsp. lactis BB-12 improves the state anxiety and sports performance of young divers under stress situations: a single-arm, prospective proof-of-concept study”. Frontiers in Psychology 11 (2021): 3710.
84. Tian P., et al. “Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial”. Brain, Behavior, and Immunity 100 (2022): 233-241.
85. Allen A P., et al. “Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers”. Translational psychiatry11 (2016): e939-e939.
86. Lew LC., et al. “Probiotic Lactobacillus plantarum P8 alleviated stress and anxiety while enhancing memory and cognition in stressed adults: A randomised, double-blind, placebo-controlled study”. Clinical Nutrition5 (2019): 2053-2064.
87. Saccarello A., et al. “Oral administration of S-Adenosylmethionine (SAMe) and Lactobacillus plantarum HEAL9 improves the mild-to-moderate symptoms of depression: a randomized, double-blind, placebo-controlled study”. The Primary Care Companion for CNS Disorders4 (2020): 23164.
88. Meng X., et al. “Clinical application value of Lactobacillus plantarum PS128 in patients with anxiety disorders”. Clinical Psychopharmacology and Neuroscience3 (2022): 560.
89. Chen H M., et al. “Psychophysiological effects of lactobacillus plantarum ps128 in patients with major depressive disorder: a preliminary 8-week open trial”. Nutrients11 (2021): 3731.
90. Ho Y T., et al. “Effects of Lactobacillus plantarum ps128 on depressive symptoms and sleep quality in self-reported insomniacs: A randomized, double-blind, placebo-controlled pilot trial”. Nutrients8 (2021): 2820.
91. Wauters L., et al. “Lactobacillus rhamnosus CNCM I-3690 decreases subjective academic stress in healthy adults: A randomized placebo-controlled trial”. Gut microbes1 (2022): 2031695.
92. Dinan TG., et al. “Psychobiotics: a novel class of psychotropic”. Biological psychiatry10 (2013): 720-726.
93. Zou R., et al. “Psychobiotics as a novel strategy for alleviating anxiety and depression”. Journal of Functional Foods 86 (2021): 104718.
94. Liu YW., et al. “Effects of Lactobacillus plantarum PS128 on children with autism spectrum disorder in Taiwan: a randomized, double-blind, placebo-controlled trial”. Nutrients4 (2019): 820.
95. Liu Y., et al. “Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression”. Clinical Gastroenterology and Hepatology11 (2016): 1602-1611.
96. Chung Y C., et al. “Fermented milk of Lactobacillus helveticus IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults”. Journal of Functional Foods 10 (2014): 465-474.
97. Ohsawa K., et al. “Lactobacillus helveticus-fermented milk containing lactononadecapeptide (NIPPLTQTPVVVPPFLQPE) improves cognitive function in healthy middle-aged adults: A randomised, double-blind, placebo-controlled trial”. International Journal of Food Sciences And Nutrition3 (2018): 369-376.
98. Tillisch K., et al. “Consumption of fermented milk product with probiotic modulates brain activity”. Gastroenterology7 (2013): 1394-1401.
99. Akbari E., et al. “Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial”. Frontiers in Aging Neuroscience 8 (2016): 256.
100. Hwang K., et al. “Para‐psychobiotic Lactobacillus gasseri CP2305 ameliorates stress‐related symptoms and sleep quality”. Journal of Applied Microbiology6 (2017): 1561-1570.
101. Butler M I., et al. “Recipe for a healthy gut: intake of unpasteurised milk is associated with increased lactobacillus abundance in the human gut microbiome”. Nutrients5 (2020): 1468.
102. Meile L., et al. “Safety assessment of dairy microorganisms: Propionibacterium and Bifidobacterium”. International Journal of Food Microbiology3 (2008): 316-320.
103. Esaiassen E., et al. “Bifidobacterium bacteremia: clinical characteristics and a genomic approach to assess pathogenicity”. Journal of Clinical Microbiology7 (2017): 2234-2248.
104. Takiguchi Y., et al. “Peribronchial connective tissue infection caused by Bifidobacterium Longum and veillonella species mimicking lung cancer”. Internal Medicine3 (2021): 453-456.
105. Sharma R., et al. “Psychobiotics: The next-generation probiotics for the brain”. Current Microbiology 78 (2021): 449-463.
106. Zhai Q., et al. “A next generation probiotic, Akkermansia muciniphila”. Critical Reviews in Food Science and Nutrition 19 (2019): 3227-3236.
107. Martín R., et al. “Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic”. Frontiers in Microbiology 8 (2017): 1226.
108. Kallassy J., et al. “Strains of Faecalibacterium prausnitzii and its extracts reduce blood glucose levels, percent HbA1c, and improve glucose tolerance without causing hypoglycemic side effects in diabetic and prediabetic mice”. BMJ Open Diabetes Research and Care3 (2023): e003101.
109. Pathak R., et al. “Time dependent growth pattern study of Lactobacillus spp. and Bifidobacterium spp. in the presence of Tartrazine; an azo dye”. Journal of Microbiology and Experimentation 1 (2023): 20-24.
110. Lalou K. “DuPont N&B launches Howaru Calm to tackle stress and support mental well-being, nutritioninsight” (2021).
111. National Institute of Health. “Probiotics: What you need to know”. National centre for complementery health (2019).
112. Grand View Research. “Probiotics Market Size, Share and Trends Analysis Report By Application (Food and Beverages, Dietary Supplements By End Use (Human, Animal By Sales Channel, By Formulation, And Segment Forecasts, 2019 – 2025” (2019).
113. Future Market Insights. “Psychobiotic Supplements Market: Global Industry Analysis 2016-2020 and Opportunity Assessment 2021-2031” (2021).

Citation

Citation: Prem Saran Tirumalai., et al. “Exploring the Microbiome through Probiotics and Psychobiotics: Deciphering the Gut-Brain Link".Acta Scientific Microbiology 6.12 (2023): 03-21.

Copyright

Copyright: © 2023 Prem Saran Tirumalai., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.